DAWN CH Clinical Haematology Software Newsletter

March 2016 DAWN Haematology Software E-Newsletter
In this issue:
Support desk holiday closures
We just want to let everyone know that we have UK public holidays on Friday 25th and Monday 28th of March 2016.

Please note that the support desk will not be open on these dates. If you have any problems or issues on these dates, please email us at and a member of staff will be in contact with you the next working day.

DAWN Score Cards - patient or healthcare professional-completed online disease activity questionnaires
DAWN Score Cards for Clinical Haematology is a suite of web-based questionnaires for assessing disease activity.

The questionnaires can be completed by healthcare professionals or by patients themselves and the results exported and imported into other systems such as electronic medical record systems or specialist haematology systems such as DAWN CH.

Images of the completed questionnaires can also be captured as PDF files and attached to patient records.

Contact the 4S DAWN team at for more information.
Improve Communication with SMS/Email functionality from DAWN
The DAWN database for chronic disease monitoring can now be configured to generate SMS/text message or email alerts for patients and healthcare professionals.

Several timed messages can be sent to participating patients to remind them that their next blood monitoring test is due in a few day's time.

The DAWN database can also be set to prompt the lead nurse or doctor that recent results require review in the DAWN database.

Contact the 4S DAWN team at for more information.

Patient Demographics Interface - Best Practice
For those of you who have a patient demographics interface from your PAS system into DAWN CH, please remember to make any changes relating to the patient's contact details, ie, address, within your PAS system rather than the DAWN CH system. Once a change has been made within the PAS system, this information will automatically get updated within DAWN CH.

If you amend details within the DAWN CH system first, then there is a chance that these could get overwritten with the old information from the PAS system. If you have any queries at all, please contact us at

Did you know...

Race May Influence Clinical Outcomes in Myeloproliferative Neoplasms
Non-Caucasian patients with myeloproliferative neoplasms have an increased risk for developing vascular complications, while Caucasian patients have a higher risk of progression to myelofibrosis, a study published in the journal Clinical Lymphoma, Myeloma, & Leukemia has shown.

The Philadelphia chromosome-negative myeloproliferative neoplasms, such as polycythemia vera, essential thrombocytopenia, and myelofibrosis, are characterized by an increased risk for developing thrombotic and hemorrhagic complications. Although large retrospective studies have attributed racial disparities in myeloproliferative neoplasm outcomes to access to health care, researchers hypothesized that race may impact outcomes.

NICE turns down Janssen's Imbruvica for CLL
Patients with chronic lymphocytic leukaemia (CLL) living in England and Wales are unlikely to get access to Janssen UK’s Imbruvica on the NHS after the drug was turned down by cost regulators.

The National Institute for Health and Care Excellence has published preliminary guidelines rejecting the drug’s use because uncertainties in the company’s submission have cast a shadow of doubt over whether Imbruvica (ibrutinib) is a cost-effective use of NHS resources in the this setting.

Janssen said it is “extremely disappointed” with NICE’s position which, it argues, is “in stark contrast to the recommendations of 48 countries globally which have opted to fund or reimburse the medicine including 27 European countries”.

Obinutuzumab/Venetoclax Combo Highly Effective in CLL
Treatment with the combination of the CD20 inhibitor obinutuzumab (Gazyva) and the BCL-2 inhibitor venetoclax was tolerable and demonstrated promising signs of efficacy for elderly patients with previously untreated chronic lymphocytic leukemia (CLL) and comorbidities, according to preliminary data from the CLL14 trial.

After 3 cycles of treatment with venetoclax and obinutuzumab, the overall response rate (ORR) was 92%. After 6 cycles of treatment with the combination, the ORR rose to 100%. Based on a recommendation from an Independent Data Monitoring Committee review, the randomized portion of the trial was opened in August 2015 and has already enrolled 120 patients.

Follow us on our LinkedIn Page!
4S DAWN Clinical Software has a new LinkedIn company page where you can keep up to date with all of the latest news and developments. Follow us and join our LinkedIn community: CLICK HERE

Copyright © 2016 4S Information Systems Ltd, All rights reserved.